These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35818703)

  • 1. Cost-Benefit Analysis of Tafenoquine for Radical Cure of
    Suh J; Kim JH; Kim JD; Kim C; Choi JY; Lee J; Yeom JS
    J Korean Med Sci; 2022 Jul; 37(27):e212. PubMed ID: 35818703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated impact of tafenoquine for Plasmodium vivax control and elimination in Brazil: A modelling study.
    Nekkab N; Lana R; Lacerda M; Obadia T; Siqueira A; Monteiro W; Villela D; Mueller I; White M
    PLoS Med; 2021 Apr; 18(4):e1003535. PubMed ID: 33891582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study.
    Brito M; Rufatto R; Brito-Sousa JD; Murta F; Sampaio V; Balieiro P; Baía-Silva D; Castro V; Alves B; Alencar A; Duparc S; Grewal Daumerie P; Borghini-Fuhrer I; Jambert E; Peterka C; Edilson Lima F; Carvalho Maia L; Lucena Cruz C; Maciele B; Vasconcelos M; Machado M; Augusto Figueira E; Alcirley Balieiro A; Batista Pereira D; Lacerda M
    Lancet Infect Dis; 2024 Jun; 24(6):629-638. PubMed ID: 38452779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.
    Sharma R; Sharma H; Jones S; Borghini-Fuhrer I; Domingo GJ; Gibson RA; Rolfe K; Tan L; Fiţa IG; Chen C; Bird P; Pingle A; Duparc S
    Malar J; 2024 May; 23(1):145. PubMed ID: 38741094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility of tafenoquine vs. primaquine for the radical cure (prevention of relapse) of
    Kostić M; Milosavljević MN; Stefanović S; Ranković G; Janković SM
    J Chemother; 2020 Feb; 32(1):21-29. PubMed ID: 31524099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
    Walsh DS; Wilairatana P; Tang DB; Heppner DG; Brewer TG; Krudsood S; Silachamroon U; Phumratanaprapin W; Siriyanonda D; Looareesuwan S
    Clin Infect Dis; 2004 Oct; 39(8):1095-103. PubMed ID: 15486831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    Llanos-Cuentas A; Lacerda MVG; Hien TT; Vélez ID; Namaik-Larp C; Chu CS; Villegas MF; Val F; Monteiro WM; Brito MAM; Costa MRF; Chuquiyauri R; Casapía M; Nguyen CH; Aruachan S; Papwijitsil R; Nosten FH; Bancone G; Angus B; Duparc S; Craig G; Rousell VM; Jones SW; Hardaker E; Clover DD; Kendall L; Mohamed K; Koh GCKW; Wilches VM; Breton JJ; Green JA
    N Engl J Med; 2019 Jan; 380(3):229-241. PubMed ID: 30650326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single dose tafenoquine for preventing relapse in people with plasmodium vivax malaria-an updated meta-analysis.
    Anjum MU; Naveed AK; Mahmood SN; Naveed OK
    Travel Med Infect Dis; 2020; 36():101576. PubMed ID: 32036012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: A cost-effectiveness analysis using a transmission model.
    Price DJ; Nekkab N; Monteiro WM; Villela DAM; Simpson JA; Lacerda MVG; White MT; Devine A
    PLoS Med; 2024 Jan; 21(1):e1004255. PubMed ID: 38194420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Llanos-Cuentas A; Lacerda MV; Rueangweerayut R; Krudsood S; Gupta SK; Kochar SK; Arthur P; Chuenchom N; Möhrle JJ; Duparc S; Ugwuegbulam C; Kleim JP; Carter N; Green JA; Kellam L
    Lancet; 2014 Mar; 383(9922):1049-58. PubMed ID: 24360369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a
    Seong H; Suh J; Choi JY; Lee J; Yeom JS
    Front Public Health; 2024; 12():1423004. PubMed ID: 39238542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
    Watson J; Taylor WRJ; Bancone G; Chu CS; Jittamala P; White NJ
    PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006440. PubMed ID: 29677199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.
    Devine A; Battle KE; Meagher N; Howes RE; Dini S; Gething PW; Simpson JA; Price RN; Lubell Y
    PLoS Med; 2021 Jun; 18(6):e1003614. PubMed ID: 34061843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study.
    Sutanto I; Soebandrio A; Ekawati LL; Chand K; Noviyanti R; Satyagraha AW; Subekti D; Santy YW; Crenna-Darusallam C; Instiaty I; Budiman W; Prasetya CB; Lardo S; Elyazar I; Duparc S; Cedar E; Rolfe K; Fernando D; Berni A; Jones S; Kleim JP; Fletcher K; Sharma H; Martin A; Taylor M; Goyal N; Green JA; Tan LK; Baird JK
    Lancet Infect Dis; 2023 Oct; 23(10):1153-1163. PubMed ID: 37236221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
    Rajapakse S; Rodrigo C; Fernando SD
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010458. PubMed ID: 25921416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Operational feasibility of Plasmodium vivax radical cure with tafenoquine or primaquine following point-of-care, quantitative glucose-6-phosphate dehydrogenase testing in the Brazilian Amazon: a real-life retrospective analysis.
    Brito M; Rufatto R; Murta F; Sampaio V; Balieiro P; Baía-Silva D; Castro V; Alves B; Alencar A; Duparc S; Grewal Daumerie P; Borghini-Fuhrer I; Jambert E; Peterka C; Edilson Lima F; Carvalho Maia L; Lucena Cruz C; Maciele B; Vasconcelos M; Machado M; Augusto Figueira E; Alcirley Balieiro A; Menezes A; Ataídes R; Batista Pereira D; Lacerda M
    Lancet Glob Health; 2024 Mar; 12(3):e467-e477. PubMed ID: 38365417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
    Lacerda MVG; Llanos-Cuentas A; Krudsood S; Lon C; Saunders DL; Mohammed R; Yilma D; Batista Pereira D; Espino FEJ; Mia RZ; Chuquiyauri R; Val F; Casapía M; Monteiro WM; Brito MAM; Costa MRF; Buathong N; Noedl H; Diro E; Getie S; Wubie KM; Abdissa A; Zeynudin A; Abebe C; Tada MS; Brand F; Beck HP; Angus B; Duparc S; Kleim JP; Kellam LM; Rousell VM; Jones SW; Hardaker E; Mohamed K; Clover DD; Fletcher K; Breton JJ; Ugwuegbulam CO; Green JA; Koh GCKW
    N Engl J Med; 2019 Jan; 380(3):215-228. PubMed ID: 30650322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the impact of rapid diagnostic tests on
    Kim JH; Suh J; Lee WJ; Choi H; Kim JD; Kim C; Choi JY; Ko R; Kim H; Lee J; Yeom JS
    BMJ Glob Health; 2021 Feb; 6(2):. PubMed ID: 33593755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 2D6 profiles and anti-relapse efficacy of tafenoquine against
    Dowd S; Chen N; Gatton ML; Edstein MD; Cheng Q
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0101423. PubMed ID: 37971260
    [No Abstract]   [Full Text] [Related]  

  • 20. Radical cure for Plasmodium vivax malaria after G6PD qualitative testing in four provinces in Cambodia, results from Phase I implementation.
    Lek D; Tsai YC; Hirano J; Sovannaroth S; Bunreth V; Vonn P; Vannthen O; Bunkea T; Samphornarann T; Sokomar N; Sarath M; Kheang ST; Wong E; Burbach MK; Hughes J; Rekol H
    Malar J; 2024 Feb; 23(1):56. PubMed ID: 38395925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.